A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)

Inclusion Criteria

• •Adults (aged 18 or over at time of first administration of rVWF) who have provided informed consent and used rVWF within its licensed indication.
• •Participants who have been diagnosed with congenital von Willebrand disease.
• •Confirmed instance of
• •* at least one bleed (either a new bleed or ongoing bleed treated under a treatment switch) treated on-demand with rVWF between 01-Oct-2020 and 30-Jun- 2022 and/or
• •* treatment to prevent and treat surgical bleeds with rVWF between 01-Oct-2020 and 30-Jun-2022